PHILADELPHIA--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI). Currently available adenosine agonists must be used with caution or are contraindicated in patients with asthma and COPD. The findings, presented at the annual meeting of the American Society of Nuclear Cardiology (ASNC2010) and published in the Journal of Nuclear Cardiology, support the potential advantage of Stedivaze for use in these populations, which account for approximately 10 percent of the 7.6 million MPI tests performed annually.
